Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World
Hogan Lovells, 12 PM EDT
Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World. In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J, and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.
- Lauren Battaglia, Hogan Lovells
- Mark Ford, Wilmer Hale
- Barry Harris, Economists Inc.
- Heather Johnson, FTC
- Jacob Westin, GlaxoSmithKline
Antitrust Section Members,
Government, Non-profit Employees,
$25 Other Non-Members
Explore Section benefits or call
800-285-2221 to join. Code RAT14IP25.
For this and all upcoming events visit http://AmBar.org/ATEvents.
The ABA is not seeking CLE credit for this program.
Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.